Formulation B
Sponsors
GlaxoSmithKline, Northwestern University, Janssen Sciences Ireland UC, Pfizer, Lyndra Inc.
Conditions
Acne VulgarisGastric RetentionHealthyHealthy VolunteersMultiple SclerosisPneumococcal Disease, InvasiveRespiratory Tract InfectionRespiratory Tract Infections
Early Phase 1
Phase 1
Bioequivalence and Food Effect Study in Healthy Volunteers
CompletedNCT00495274
Start: 2007-07-02End: 2007-09-26Updated: 2017-08-07
Firategrast (SB683699) Surface Area Study in Multiple Sclerosis Patients
CompletedNCT00548769
Start: 2007-04-21End: 2007-11-26Updated: 2017-08-01
Study to Evaluate Taste Profile of Different JNJ-53718678 Oral Liquid Formulations in Healthy Participants
CompletedNCT02426632
Start: 2015-03-04End: 2015-04-24Updated: 2018-05-15
Sustained Release Oral Formulation For Treatment Of Parkinsons Disease
Not yet recruitingNCT07709741
Start: 2026-09-30End: 2027-06-30Target: 32Updated: 2026-08-10
Phase 2
A Study to Describe the Safety and Immunogenicity of a RSV Vaccine in Healthy Adults
CompletedNCT03529773
Start: 2018-04-18End: 2020-12-28Updated: 2022-03-03
A Study to Evaluate the Safety and Immunogenicity of an Adjuvanted RSV Vaccine in Healthy Older Adults
TerminatedNCT03572062
Start: 2018-06-05End: 2020-08-19Updated: 2021-08-26
Phase 2 Trial to Evaluate Safety and Immunogenicity of Inventprise's (IVT) 25-valent Pneumococcal Conjugate Vaccine (IVT PCV-25) in Healthy Infants
Active, not recruitingNCT06790290
Start: 2025-01-27End: 2026-12-31Updated: 2025-09-02